Wealthfront Advisers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $47.9M | Buy |
190,484
+7,550
| +4% | +$1.62M | 0.09% | 87 |
|
|
2026
Q1 | $39.8M | Buy |
182,934
+2,931
| +2% | +$650K | 0.09% | 87 |
|
|
2025
Q4 | $41.1M | Buy |
180,003
+4,603
| +3% | +$1.05M | 0.09% | 78 |
|
|
2025
Q3 | $40.6M | Buy |
175,400
+14,845
| +9% | +$3.02M | 0.1% | 76 |
|
|
2025
Q2 | $29.8M | Sell |
160,555
-268
| -0.2% | -$49.8K | 0.08% | 86 |
|
|
2025
Q1 | $33.7M | Buy |
160,823
+11,726
| +8% | +$2.28M | 0.09% | 73 |
|
|
2024
Q4 | $26.5M | Buy |
149,097
+9,608
| +7% | +$1.77M | 0.08% | 80 |
|
|
2024
Q3 | $27.5M | Buy |
139,489
+5,380
| +4% | +$1M | 0.08% | 70 |
|
|
2024
Q2 | $23M | Sell |
134,109
-3,744
| -3% | -$620K | 0.08% | 76 |
|
|
2024
Q1 | $25.1M | Buy |
137,853
+6,615
| +5% | +$1.14M | 0.09% | 67 |
|
|
2023
Q4 | $20.3M | Sell |
131,238
-11,104
| -8% | -$1.62M | 0.08% | 69 |
|
|
2023
Q3 | $21.2M | Buy |
142,342
+16,107
| +13% | +$2.36M | 0.09% | 68 |
|
|
2023
Q2 | $17M | Sell |
126,235
-57,358
| -31% | -$8.41M | 0.07% | 74 |
|
|
2023
Q1 | $29.3M | Sell |
183,593
-2,081
| -1% | -$318K | 0.13% | 47 |
|
|
2022
Q4 | $30M | Buy |
185,674
+12,451
| +7% | +$1.91M | 0.15% | 45 |
|
|
2022
Q3 | $23.2M | Buy |
173,223
+8,913
| +5% | +$1.28M | 0.12% | 44 |
|
|
2022
Q2 | $25.2M | Buy |
164,310
+23,252
| +16% | +$3.55M | 0.13% | 42 |
|
|
2022
Q1 | $22.9M | Buy |
141,058
+13,043
| +10% | +$1.89M | 0.1% | 46 |
|
|
2021
Q4 | $17.3M | Buy |
128,015
+10,538
| +9% | +$1.24M | 0.07% | 62 |
|
|
2021
Q3 | $12.7M | Buy |
117,477
+15,313
| +15% | +$1.75M | 0.06% | 66 |
|
|
2021
Q2 | $11.5M | Buy |
102,164
+9,608
| +10% | +$1.08M | 0.05% | 62 |
|
|
2021
Q1 | $10M | Buy |
92,556
+3,997
| +5% | +$428K | 0.05% | 62 |
|
|
2020
Q4 | $9.49M | Sell |
88,559
-7,449
| -8% | -$716K | 0.06% | 59 |
|
|
2020
Q3 | $8.41M | Sell |
96,008
-8,382
| -8% | -$789K | 0.06% | 63 |
|
|
2020
Q2 | $10.2M | Buy |
104,390
+15,628
| +18% | +$1.38M | 0.08% | 44 |
|
|
2020
Q1 | $6.76M | Buy |
88,762
+18,730
| +27% | +$1.6M | 0.06% | 53 |
|
|
2019
Q4 | $6.2M | Buy |
70,032
+6,862
| +11% | +$570K | 0.05% | 68 |
|
|
2019
Q3 | $4.78M | Buy |
63,170
+5,492
| +10% | +$377K | 0.04% | 74 |
|
|
2019
Q2 | $4.19M | Sell |
57,678
-4,222
| -7% | -$332K | 0.04% | 80 |
|
|
2019
Q1 | $4.99M | Sell |
61,900
-28,507
| -32% | -$2.33M | 0.05% | 73 |
|
|
2018
Q4 | $8.34M | Buy |
+90,407
| New | +$7.95M | 0.09% | 44 |
|
Other funds holding ABBV
Wealthfront Advisers's ABBV Position: Q2 2026 in Review
Wealthfront Advisers increased its AbbVie (ABBV) stake by 4.1% in Q2 2026, buying an estimated $1.62M and bringing the position to 190,484 shares worth $47.9M. The position accounts for 0.09% of the portfolio, ranked #87.
Wealthfront Advisers first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Wealthfront Advisers held 190,484 shares of AbbVie worth $47.9M as of Q2 2026.
- Wealthfront Advisers bought 7,550 AbbVie shares in Q2 2026, an estimated $1.62M.
- AbbVie made up 0.09% of Wealthfront Advisers's portfolio in Q2 2026, its #87 holding.
- Wealthfront Advisers first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.